These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells. Cragg MS; Zhang L; French RR; Glennie MJ Br J Cancer; 1999 Feb; 79(5-6):850-7. PubMed ID: 10070880 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. Wang X; Campoli M; Ko E; Luo W; Ferrone S J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013 [TBL] [Abstract][Full Text] [Related]
25. Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Macor P; Mezzanzanica D; Cossetti C; Alberti P; Figini M; Canevari S; Tedesco F Cancer Res; 2006 Apr; 66(7):3876-83. PubMed ID: 16585216 [TBL] [Abstract][Full Text] [Related]
26. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982 [TBL] [Abstract][Full Text] [Related]
27. Staphylococcal protein A binding to the Fab fragments of mouse monoclonal antibodies. Young WW; Tamura Y; Wolock DM; Fox JW J Immunol; 1984 Dec; 133(6):3163-6. PubMed ID: 6386983 [TBL] [Abstract][Full Text] [Related]
28. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619 [TBL] [Abstract][Full Text] [Related]
29. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. Takeya H; Mori T; Gabazza EC; Kuroda K; Deguchi H; Matsuura E; Ichikawa K; Koike T; Suzuki K J Clin Invest; 1997 May; 99(9):2260-8. PubMed ID: 9151800 [TBL] [Abstract][Full Text] [Related]
30. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Nielsen UB; Adams GP; Weiner LM; Marks JD Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810 [TBL] [Abstract][Full Text] [Related]
31. [Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody]. Liu YX; Fan DM; Xiong DS; Xu YF; Shao XF; Xu YS; Peng H; Yang M; Qin L; Zhu ZP; Yang CZ Ai Zheng; 2003 Dec; 22(12):1249-53. PubMed ID: 14693045 [TBL] [Abstract][Full Text] [Related]
32. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319 [TBL] [Abstract][Full Text] [Related]
33. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components. Mezzanzanica D; Canevari S; Ménard S; Pupa SM; Tagliabue E; Lanzavecchia A; Colnaghi MI Int J Cancer; 1988 Apr; 41(4):609-15. PubMed ID: 3258590 [TBL] [Abstract][Full Text] [Related]
34. The fate of antibodies bound to the surface of tumor cells in vitro. Kyriakos RJ; Shih LB; Ong GL; Patel K; Goldenberg DM; Mattes MJ Cancer Res; 1992 Feb; 52(4):835-42. PubMed ID: 1737345 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. Mantovani L; Ménard S; Mezzanzanica D; Miotti S; Pupa SM; Colnaghi MI Br J Cancer Suppl; 1990 Jul; 10():15-7. PubMed ID: 2383475 [TBL] [Abstract][Full Text] [Related]
36. The interaction of monoclonal antibodies with MHC class I antigens on mouse spleen cells. I. Analysis of the mechanism of binding. Dower SK; Ozato K; Segal DM J Immunol; 1984 Feb; 132(2):751-8. PubMed ID: 6690617 [TBL] [Abstract][Full Text] [Related]
37. Development and validation of an antigen-binding capture ELISA for native and putrescine-modified anti-tetanus F(ab')2 fragments for the assessment of the cellular uptake and plasma kinetics of the antibodies. Welfringer F; d'Athis P; Scherrmann JM; Hervé F J Immunol Methods; 2005 Dec; 307(1-2):82-95. PubMed ID: 16305797 [TBL] [Abstract][Full Text] [Related]
38. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Mantovani LT; Miotti S; Ménard S; Canevari S; Raspagliesi F; Bottini C; Bottero F; Colnaghi MI Eur J Cancer; 1994; 30A(3):363-9. PubMed ID: 8204360 [TBL] [Abstract][Full Text] [Related]
39. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358 [TBL] [Abstract][Full Text] [Related]
40. Conformational changes in the rod domain of human keratin 8 following heterotypic association with keratin 18 and its implication for filament stability. Waseem A; Karsten U; Leigh IM; Purkis P; Waseem NH; Lane EB Biochemistry; 2004 Feb; 43(5):1283-95. PubMed ID: 14756564 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]